Pfizer Inc. $PFE Shares Purchased by Evelyn Partners Investment Management Services Ltd

Evelyn Partners Investment Management Services Ltd grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 589.3% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 20,701 shares of the biopharmaceutical company’s stock after purchasing an additional 17,698 shares during the period. Evelyn Partners Investment Management Services Ltd’s holdings in Pfizer were worth $482,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the first quarter worth about $27,000. Curio Wealth LLC boosted its holdings in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares during the period. Bayforest Capital Ltd acquired a new stake in Pfizer in the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer during the second quarter valued at approximately $29,000. Finally, Evelyn Partners Asset Management Ltd acquired a new position in shares of Pfizer during the second quarter worth $33,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE stock opened at $25.02 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The stock has a market capitalization of $142.26 billion, a price-to-earnings ratio of 13.31, a PEG ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock’s fifty day moving average is $24.84 and its two-hundred day moving average is $24.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Scotiabank initiated coverage on shares of Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target on the stock. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Morgan Stanley reduced their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Finally, Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.